tradingkey.logo

Travere Therapeutics Says FDA Extends Review Of SNDA For Filspari (Sparsentan) In FSGS

ReutersJan 13, 2026 6:26 PM

- Travere Therapeutics Inc TVTX.O:

  • TRAVERE THERAPEUTICS ANNOUNCES FDA EXTENDS REVIEW OF SNDA FOR FILSPARI® (SPARSENTAN) IN FSGS

  • TRAVERE THERAPEUTICS INC - NEW PDUFA TARGET ACTION DATE SET FOR APRIL 13, 2026

  • TRAVERE THERAPEUTICS INC - NO ADDITIONAL SAFETY OR MANUFACTURING INFO REQUESTED FOR FILSPARI

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI